BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...SVP of regulatory affairs and Jonae Barnes as SVP of IR and corporate communications.Oral delivery company Chiasma Inc....
...– Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL Therapeutics Inc. miRagen Therapeutics Inc. Atea Pharmaceuticals Inc. Chiasma Inc. Tiziana...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...Inc. (NASDAQ:BLUE). The company also promoted Jennifer Wellman from senior VP of regulatory and quality to COO. Chiasma Inc....
...Richard Makara, Cara’s VP, head of accounting and comptroller, had been interim CFO. BC Staff insitro PureTech Kaleido Biosciences Arcus Biosciences Akouos Chiasma AZTherapies Cara...
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...late Thursday, a day before FDA issued decisions on therapies from AbbVie Inc. (NYSE:ABBV) and Chiasma Inc....
...franchise to Pernix Therapeutics Holdings Inc., which in February 2019 filed for bankruptcy. AbbVie setback, Chiasma...
...determine next steps. Molecular Partners’ stock fell CHF7.14 (32%) to CHF15.36 on Friday. FDA approved Chiasma’s...
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...play Imvax Inc. as CSO. Exley was VP of cellular immunology at AgenTus Therapeutics S.A. Chiasma Inc....
...who has been a strategic adviser for the chronic diseases company since 2018, had been Chiasma’s...
...launch of its Disqver platform to the European market. Robin Sawka, BioCentury Staff Silverback Therapeutics Inc. Incyte Bicycle Therapeutics Ltd. Chiasma Inc. Regenacy...
BioCentury | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

...treat multiple alternative pathway diseases. Chiasma jumps after Mycapssa meets in Phase III for acromegaly Chiasma Inc....
...of somatostatin analog Mycapssa octreotide met the primary and secondary endpoints in the Phase III CHIASMA...
...maintained their IGF-1 response after nine months compared to 19% of patients on placebo (p=0.008). Chiasma...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Co. Ltd. (Tokyo:4547) Avacopan Treat antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis Phase III data 4Q19 Chiasma Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...injection Advanced squamous cell carcinoma of the head and neck (SCCHN) Phase III data 1H19 Chiasma Inc....
BioCentury | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

...LDK378) AbbVie Inc. Advenchen Laboratories LLC Amgen Inc. AstraZeneca Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH Celgene Corp. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Chiasma Inc. Chugai...
BioCentury | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

...HKEX:6160) and Pfizer for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia; and Mycapssa octreotide from Chiasma Inc....
BioCentury | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

...hired Anand Varadan as EVP and chief commercial officer. He was chief commercial officer at Chiasma Inc....
Items per page:
1 - 10 of 66
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...SVP of regulatory affairs and Jonae Barnes as SVP of IR and corporate communications.Oral delivery company Chiasma Inc....
...– Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL Therapeutics Inc. miRagen Therapeutics Inc. Atea Pharmaceuticals Inc. Chiasma Inc. Tiziana...
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...Inc. (NASDAQ:BLUE). The company also promoted Jennifer Wellman from senior VP of regulatory and quality to COO. Chiasma Inc....
...Richard Makara, Cara’s VP, head of accounting and comptroller, had been interim CFO. BC Staff insitro PureTech Kaleido Biosciences Arcus Biosciences Akouos Chiasma AZTherapies Cara...
BioCentury | Jun 27, 2020
Regulation

Boxed warning on Zogenix’s Dravet syndrome therapy could hamper market prospects

...late Thursday, a day before FDA issued decisions on therapies from AbbVie Inc. (NYSE:ABBV) and Chiasma Inc....
...franchise to Pernix Therapeutics Holdings Inc., which in February 2019 filed for bankruptcy. AbbVie setback, Chiasma...
...determine next steps. Molecular Partners’ stock fell CHF7.14 (32%) to CHF15.36 on Friday. FDA approved Chiasma’s...
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...play Imvax Inc. as CSO. Exley was VP of cellular immunology at AgenTus Therapeutics S.A. Chiasma Inc....
...who has been a strategic adviser for the chronic diseases company since 2018, had been Chiasma’s...
...launch of its Disqver platform to the European market. Robin Sawka, BioCentury Staff Silverback Therapeutics Inc. Incyte Bicycle Therapeutics Ltd. Chiasma Inc. Regenacy...
BioCentury | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

...treat multiple alternative pathway diseases. Chiasma jumps after Mycapssa meets in Phase III for acromegaly Chiasma Inc....
...of somatostatin analog Mycapssa octreotide met the primary and secondary endpoints in the Phase III CHIASMA...
...maintained their IGF-1 response after nine months compared to 19% of patients on placebo (p=0.008). Chiasma...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Co. Ltd. (Tokyo:4547) Avacopan Treat antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis Phase III data 4Q19 Chiasma Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...injection Advanced squamous cell carcinoma of the head and neck (SCCHN) Phase III data 1H19 Chiasma Inc....
BioCentury | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

...LDK378) AbbVie Inc. Advenchen Laboratories LLC Amgen Inc. AstraZeneca Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH Celgene Corp. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Chiasma Inc. Chugai...
BioCentury | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

...HKEX:6160) and Pfizer for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia; and Mycapssa octreotide from Chiasma Inc....
BioCentury | Jun 25, 2018
Company News

Management tracks: Nordic Nanovector, Molecular Partners

...hired Anand Varadan as EVP and chief commercial officer. He was chief commercial officer at Chiasma Inc....
Items per page:
1 - 10 of 66